Gilead Sciences Inc. (GILD) exhibits 78.8% gross margins and 21.0% return on invested capital within Health Care (Biotechnology: Biological Products (No Diagnostic Substances)), balanced against a 21.0x enterprise multiple and 4.8% implied options volatility.
Sustained 78.8% gross profitability converts into 34.0% operating margin and 21.0% ROIC, outpacing sector cost of capital.
ROIC: 21.0% // GM: 78.8%YoY revenue trajectory of +2.4% paired with 4.60% free cash flow yield supports self-funded R&D and capital return.
REV YOY: +2.4% // FCF YLD: 4.60%Altman Z-Score of 5.87 and Piotroski F-Score of 8/9 indicate low near-term refinancing stress.
ALTMAN Z: 5.87 // F-SCORE: 8/9Trading at 24.1x trailing P/E (22.4x Fwd P/E) leaves valuation vulnerable if real 10Y TIPS yields spike.
P/E: 24.1x // EV/EBITDA: 21.0xOptions market prices a ±5.2% implied move with a 0.85 put/call ratio around $170.68 max pain.
IMPL MOVE: ±5.2% // P/C: 0.85Elevated industry capital intensity and customer concentration in Biotechnology: Biological Products (No Diagnostic Substances) require continuous execution to defend 28.9% net margins.
NET MARGIN: 28.9% // D/E: 0.97x| FILER | SIDE | $ VALUE |
|---|---|---|
| INSPECT FULL OWNERSHIP LEDGER IN OWN <GO> | ||
| STRIKE / EXP | TYPE | PREMIUM |
|---|---|---|
| INSPECT GEX & CHAIN IN OPT <GO> | ||
Unblur the exact $50,000 delta-adjusted ETF/options hedge ratio for GILD & activate live FRED threshold breach alerts.